ASTRAZENECA PLC

Explore how market trends, reimbursement models, and operational hurdles shape the future of healthcare delivery—and how ROI, NPV, and cost‑efficiency metrics drive investment decisions in tech‑driven care.

Explore how AstraZeneca’s new U.S. approval for Etcamah—an ESR1‑targeting SERD/CDK4/6 combo—boosts its oncology strategy, market access, and shareholder value.

Phase‑III results show AstraZeneca’s Tezspire achieves 57% histologic remission and significant dysphagia relief in eosinophilic esophagitis—clinically meaningful, safe, and durable.

Discover how AstraZeneca’s strategic M&A, pipeline resilience, and market‑access gains keep investors confident amid patent cliffs and fierce competition.

How AstraZeneca balances oncology trial results, payer demands, and ROI – why the Tagrisso‑Orpathys combo wins and volrustomig stops.

How a possible AstraZeneca‑BMS merger could reshape market access, innovation, and share pricing – dive into the numbers, risks, and upside of this £400 bn pharma deal.

Explore the $400 billion AstraZeneca‑BMS merger: how it could reshape oncology, boost R&D, and challenge regulators while reshaping patient access and healthcare costs.

Discover how AstraZeneca’s upcoming first‑half results will shape healthcare pricing, reimbursement, and operational strategy in 2024.

EU approves AstraZeneca’s Etcamah oral SERD for ER‑positive breast cancer, boosting early ctDNA‑guided treatment and expanding hormone‑positive options.

Discover how AstraZeneca’s $600 M deal with Chinese biotech Dizhē Zhìyào brings an oral EGFR inhibitor to market, offering faster, cost‑effective treatment for EGFR‑mutant lung cancer patients.